



Our DNA

Vision

The Challenger

Business Idea

This will happen through unique relationships, best in class decisionmaking and cost effective solutions

Main targets

Cost and quality leadership

Profitable growth

Top 3

Values

Credible

Innovative/Open

Bold

Committed



New information

PROTECTOR insurance

SCR-ratio up 19% points, YTD equity return > MNOK 350, 3-year CR 90-92%


- New BNOK 1.9 reinsurance deal on WC Denmark/Norway signed March 9th
 - The deal confirm reserve quality
 - Protectors SCR-ratio increases with 19%-points, everything else equal
 - Very attractive cost of capital
- YTD equity portfolio return > MNOK 350
 - Remember, these gains are mainly unrealized and volatility must be expected
- Long-term (3 years) combined ratio target changed from 94% to 90-92%
- New dividend policy decided in the board
 - A flexible policy where priority 1 is Insurance growth if possible
 - Excess capital (SCR-ratio > 180%) will be distributed to shareholders over time
 - Quarterly dividend will be considered (but remember, flexibility comes first)


Product mix development¹ – towards short tail

Reduced risk profile and reduced capital consumption



- Short tail from 34% in 2008 to 80% in 2021
- Long tail attractiveness decreasing as risk free interest rate decline or disappear.
- Geographical diversification increased; four countries at critical mass
- Motor increasing from 9% in 2008 to 35% in 2021
- Avg. capital consumption per GWP in current portfolio at 31%, versus 45% in 2014








Capital consumption going down quickly

Increased ROE and shareholder distribution





WC all countries COI, Liability, EL UK, Other Illness Property, Motor, Accident & Other Capital consumption pr. GWP



Nordics – Back on track

Profitability improvements continuing

Profitability entering 2021
 Turn-around completed

• Cost efficiency measures Cost ratio down 1.5%-points in 2022

Quality towards market
 Measured monthly through "Broker Instant Feedback".

• Price increases in 2021 4-5%-points higher than claims inflation

Underwriting discipline
 Further de-risking, but now on a moderate level


Nordic profitability outlook 2021 Combined ratio < 90%

Growth opportunities in the Nordics
 Maintain discipline, low single digit 2021















Price increases

Will improve profitability 4-5% in 2021



Margin

Management

		2020	2021
	Very low churn on P&C. High churn on Workers Comp.	≈ 14.5%	Slightly less than 2020
-	Very large variation on products and segments. Motor much lower. Real estate average +40%.	≈ 13.0%	Less than 2020 in total. Larger variation.
	Very high churn driven by Workers Comp. Deliberate due to capital consumption.	≈ 11.9%	Slightly less than 2020
	Very low churn on all products.	≈ 21.7%	Less than 2020
	Low churn. Majority unprofitable.	≈ 13.7%	8.7% in January Higher going forward.

• Average claims inflation (all products) 3-4 % in the Nordics, higher on Motor and Real Estate



UK Summary 2016-2020

A disciplined Team Journey has just begun



• £10bn market in scope, £3bn market in focus, many years of growth ahead


Three segments

 Public UW & cost advantage

Housing: UW & cost advantage

Careful entry, one team Commercial:

- Profitable in 2019 and 2020
 - Profitable in year 4 and 5 (like in Sweden)
 - Some luck on large losses
 - Good underlying profitability
 - Improved Reinsurance terms
- Culture is key
 - Quality leader
 - Up-front investment in people for future










Disciplined growth in a large market

61% avg. annual growth since 2017 with lots more potential

£m **■** 2017 **■** 2018 **■** 2019 **■** 2020 120 110,64 100 75,91 80 59,63 60 47,06 40,50 40 31,01 22,50 20,00 18,71 17,14 20 13,82 11,21 10,65 5,64

UK GWP Growth





PROTECTOR

Public Sector GWP Development

35.00

insurance

31.01




Broker Satisfaction



Perception is reality, strong results in 2020, never compromise on quality

BSI UK 2020 - Totality



How did it happen?



Our DNA

Vision

The Challenger

Business Idea

This will happen through unique relationships, best in class decisionmaking and cost effective solutions

Culture eats strategy for breakfast!

Main targets

Cost and quality leadership

Profitable growth

Top 3

Values

Credible

Innovative/Open

Bold

Committed

It's our **DNA** - We are **The Challenger**

The real secret

Know, understand and live our DNA – every day







Our DNA


Vision

The Challenger

Business Idea



This will happen through unique relationships, best in class decisionmaking and cost effective solutions





Main targets

Cost and quality leadership

Profitable growth

Top 3

Values


Credible

Innovative/Open

Bold


Committed



























Investment is core

CAGR AUM last 5 years of 15.2%



10 925

10.1%


9 5 3 5

9 3 7 3

13 492

13.5%

- Equity share between 8.9 and 25.1% historically
 - Direct equity investments under consideration
- High Yield (HY) share between 15% and 34% historically
- Equity and HY share will vary according to assessed attractiveness > 20% RoE
 - Capital consumption differ substantially between asset classes






Equity portfolio statistics

Good performance since inception in 2014

- Equity share of total portfolio varies depending on available investment opportunities reaching hurdle
- Discount to estimated intrinsic value 26% at YE20
- Concentrated portfolio where top 5 positions will normally be 30-50% of total
 - No travel-, oil- or oil service companies









Bond portfolio statistics

PROTECTOR insurance


Immaterial losses the last 5 years. Higher risk in 2020 and start of 2021

- Low losses, -0.11% or less, every year since insourcing in 2015
 - Higher risk in 2020 than avg. last 5 years with losses of -12m or -0.11%
 - A year with higher volatility and higher losses for the general market
- "Normalized" annual loss expectation through cycle, -0.2% to -0.5%
 - Expect losses to be "chunky" with low losses in most years
 - Actual losses of course dependent on risk taking
- Avg. A- rated portfolio and risk up compared to pre-Covid
 - High-yield portfolio of NOK 4bn
- Running yield at 2.3%, before cost of risk
- Strong returns historically and relative to capital consumption
 - Avg. annual return for high yield portfolio Q115-Q420 at 7.5%

Portfolio data	31.12.20	30.09.20	31.12.19
Size bond & cash eq. (MNOK) ¹	11 603	11 788	9 757
Avg. ref. rate (NIBOR, STIBOR, etc.)	0.2%	0.1%	1.2%
Avg. spread/risk premium (bps)	210	205	89
Yield	2.3%	2.1%	2.1%
Duration	0.4	0.3	0.4
Credit duration ²	1.4	1.6	2.0
Avg. rating ³	A-	А	A+

¹ Size excludes forward foreign currency contracts

³ Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating




¹ Avg. based on official rating (>60%) and 'Protector rating' (<40%) & is based on linear rating (as usual). WARF methodology would give a somewhat lower IG-rating

² Avg. includes bank deposits

HY bond transactions January to June 2020



Protector will invest aggressively in rare situations when our assessment is outstanding risk/reward




- Severe stress tests avoids forced selling
- No "customer" will withdraw money
- We hedge all currency and have no risk of forced selling if banks demand more collateral.
- We typically have some excess capital to deploy when opportunity arise
- Flexible investment model. In March we bought High Yield.
 In the next crises it could be equities, buy-backs or something else
- Close cooperation with CEO, CFO and CRO ensures adequate risk evaluation
- All company capital allocation alternatives evaluated at all times

Bond portfolio – return and capital consumption


Focus on return on capital consumed




Protector return ex investments in HY bond funds from March '15



Protector HY return ex investments in HY bond funds from March '15





HTD outperformance at lower risk and capital consumption

²Capital consumption before any diversification effects = after tax loss in stress + capital consumption under SII







¹ Carnegie Corporate bond fund used as proxy for crossover bond funds

New long-term financial objectives – 3Y perspective



Profitable growth with a Combined Ratio 90-92%

Long-term financial objectives	Old	New	Guiding 2021
Net Combined Ratio:	94 %	90-92%	90-92%
Return on Equity (ROE):	> 20 %	> 20%	
Gross Written Premium (GWP) growth:	5 %	Disciplined	10%
Solvency II Capital Ratio (SCR):	> 150 %	> 150%	




Capital allocation – maximize shareholder return



Priority 1: Always profitable growth in insurance, if possible

Main capital allocation alternatives:



- Allocation towards profitable growth is preferred; stay disciplined
- 2 Challenging to allocate capital in times of low credit spreads and all-time-high stock markets
- How much capital should be kept for future financial market crises?
- 4 Capital base discipline; flexible distribution of excess capital if allocation cannot be made elsewhere
- An attractive alternative if meeting hurdle; will normally have to bid with significant premium

Capital allocation approach

- Determine minimum hurdle rate (RoE>20%)
- Calculate returns for all internal and external allocation alternatives available, by return and risk
- Deploy capital in the most attractive alternatives above hurdle.
- Release underperforming capital (COI, Price increases, WC Denmark and Norway as example)








Capital allocation alternatives – what have we done?


PROTECTOR insurance

Maximizing shareholder return



Differing values from P&Ls due to exchange rates applied

3	3 Dividends									
	Dividends of 14.45 per share paid out pre 2020									
Bividends of 14.45 per share paid out pre 2020										
C	Dividends	2009	2010	2012	2013	2014	2015	2016	2017	2020
P	Per share	1.25	1.50	1.20	1.75	2.00	2.25	2.25	2.25	3.00



Differing values from P&Ls due to exchange rates applied

Buy backs							
Historical buy backs – in all 26.2m shares							
Buy backs	2007	2008	2009	2010	2018		
# shares	2 718 645	14 762 900	3 348 920	955 782	4 404 622		
Average price	10.91	7.22	6.00	9.67	57.50		

Other capital allocation initiatives

Optimize sources and cost of capital



- Buying additional Large Loss Reinsurance with "0 risk" for capital reasons
- Solvency based Reinsurance, incl. retroactive option in financial turmoil
- Sale of COI reserves
- Sale of WC reserves
- Put options / investment hedging






New dividend policy in Protector decided March 4th



Flexible Shareholder distribution policy – profitable growth in insurance always priority nr 1

Solvency II ratio



Value creation in the long run

We have only just begun



- Cost leader in the world not good enough
- Quality leader in Scandinavia & UK
- Average CR last 10 years at 91.6 %
- Price increases still higher than claims inflation entering 2021, churn back to normal in Nordics
- Growing organically from 0 to > 5.5 BNOK in premiums; building a significant float
- UW discipline and Claims Handling are moments of truth
- Investment is core and delivers better than benchmark
- It's also a story of capital consumption and risk
- HTD ROE at 19%
- HTD CAGR share price at 27%








Succession: McKinsey on "Last 100 days of an CEO"

We started succession many years ago

- Fight the intuitive feeling of "a need to step back" to leave the floor to next CEO
- Continue acting as a CEO and leave the company stronger
- Do not postpone strategy development
- Act on prioritized improvement possibilities (cost cutting, new business, etc.)
- Involve management and board in a transparent structured transfer of roles and responsibilities
- Update new CEO on organization and people
- Make your (Sverre, Henrik, Hans and management) priority action plan for the last 100 days
- Have fun (added by Sverre)











Succession is about 'The Team'



Involve management in a transparent structured transfer of roles and responsibilities



Henrik Høye CEO in September, Hans Didring nr. 2 – One Team approach is what matters



Summary of today – we have only just begun

HTD ROE is 19% - new target is Combined ratio 90-92% and ROE 20%



Thank you for listening

HTD CAGR share price at 27% - what's your call?







Disclaimer



This presentation and the information contained herein have been prepared by and is the sole responsibility of Protector Forsikring ASA (the "Company"). Such information is being provided to you solely for your information and may not be reproduced, retransmitted, further distributed to any other person or published, in whole or in part, for any purpose. Failure to comply with this restriction may constitute a violation of applicable securities laws. The information and opinions presented herein are based on general information gathered at the time of writing and are therefore subject to change without notice. The Company assumes no obligations to update or correct any of the information set out herein.

These materials may contain statements about future events and expectations that are forward-looking statements. Any statement in these materials that is not a statement of historical fact including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations is a forward-looking statement that involves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions or changes in factors affecting these statements.

This presentation does not constitute or form part of, and is not prepared or made in connection with, an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purposes whatsoever on the information contained in this presentation or on its completeness, accuracy or fairness. The information in this presentation is subject to verification, completion and change. The contents of this presentation have not been independently verified. While the Company relies on information obtained from sources believed to be reliable, it does not guarantee its accuracy or completeness. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its owners, directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this presentation. None of the Company, its affiliates or any of their respective advisors or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. The Company's securities have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act"), and are offered and sold only outside the United States in accordance with an exemption from registration provided by Regulation S of the US Securities Act.

This presentation should not form the basis of any investment decision. Investors and prospective investors in securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such company and the nature of the securities. Any decision to purchase securities in the context of a proposed offering of securities, if any, should be made solely on the basis of information contained in any offering documents published in relation to such an offering. For further information about the Company, reference is made public disclosures made by the Company, such as filings made with the Oslo Stock Exchange, periodic reports and other materials available on the Company's web pages.

